Glenmark Pharmaceuticals Inc., USA launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials on July 28, 2026, targeting the hospital and institutional segment. The launch positions glenmark pharmaceuticals to capture share in a market where the reference listed drug, BRIDION® Injection, 100 mg/mL of Merck Sharp & Dohme LLC, achieved annual sales of approximately $1.6 billion for the 12-month period ending May 2026, according to IQVIA® sales data.

The filing was submitted to the National Stock Exchange of India Limited and BSE Limited under reference number 34/26-27 by Rashmi Khandelwal, Company Secretary & Compliance Officer. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to BRIDION® (NDA 022225). The product is approved only for the indications listed in Glenmark's approved label, which may differ from the approved indications of the reference listed drug.

Product Specifications

Marc Kikuchi, President & Business Head, North America, stated that the Day 1 launch reflects execution discipline and agility in Glenmark's injectable strategy. He noted that the addition strengthens the company's presence in the U.S. healthcare system by supporting supply reliability and expanding access to affordable medicines.

What the Numbers Show

The $1.6 billion annual sales figure for the BRIDION® market, derived from IQVIA® National Sales Perspectives covering retail and non-retail channels, indicates significant commercial potential for Glenmark’s new entry. As a therapeutic equivalent, Glenmark’s product competes directly with Merck Sharp & Dohme LLC’s brand within this high-value injectable category. The data source specifies that IQVIA® figures are available only for all approved RLD indications; therefore, the total addressable market for Glenmark may be narrower if its approved label covers fewer indications than the reference drug.

Glenmark Pharmaceuticals has set an ambitious target of generating 70% of its revenue from innovative drugs within the next 5-6 years, signalling a decisive strategic shift toward an innovation-based business model. The announcement highlights the company's intent to move beyond its conventional generics operations and build a stronger pipeline of novel pharmaceutical offerings.

Strategic Shift Toward Innovation

The company's forward-looking roadmap reflects a fundamental repositioning of its business, with innovative drugs expected to become the dominant revenue contributor over the medium term. This transition represents a notable departure from the generics-heavy model that has traditionally defined Glenmark Pharmaceuticals' revenue structure.

Implications for Business Model

The targeted revenue mix underscores Glenmark Pharmaceuticals' commitment to building a differentiated portfolio, with innovative drugs at its core. A shift of this magnitude—where innovative products are expected to account for nearly three-quarters of total revenue—reflects a significant long-term strategic realignment. The company's focus on innovation is positioned as a key driver of its future growth trajectory, as it looks to reduce dependence on the highly competitive generics segment.